This is the first gene editor to use a CRISPR-associated transposase to make targeted edits at therapeutically useful levels in humans.

10x Genomics has settled patent infringement lawsuits with a pair of rivals, Bruker and Vizgen, through settlements that could reshape competition within the emerging single-cell and spatial genomics ...

Element has responded to the lawsuit with a statement saying, “Element is proud of its strong history of innovation. We are reviewing the complaint and look forward to defending our innovations in ...

BioMarin agreed to shell out approximately $270 million for Inozyme Pharma, a developer whose treatments target the PPi-adenosine pathway, a key regulator of bone health and blood vessel function.

Scientists say study findings indicate that TC IV cells may represent a therapeutic target for the treatment of ...

Researchers were able to test how viruses replicate differently across various bat species and organs using the new organoid ...

How malaria parasites exploit mechanism for escaping elimination could provide novel strategies targeting chronic malaria ...

Treated with an individualized gene-editing therapy that corrects mutations directly on the genome, a patient shows ...

Estrogen-related receptors (ERRs) regulate muscle mitochondria in mice, revealing a new potential drug targets for metabolic ...

Imprint has raised $15 million to decode the body's immune memory for understanding chronic diseases, such as long-COVID and ...

Current setbacks cannot prevent gene-editing companies from advancing closer to “one-and-done” cures and new products.

HHS Secretary Robert F. Kennedy Jr. and biopharmas will negotiate drug prices individually. Kennedy could "propose a ...